[Protection of male fertility during anticancer treatment: animal experiments].
One of the best known iatrogenic effects of anticancer treatments is the sterility of young patients with a good prognosis, hence the necessity to develop a protocol enabling us to preserve male reproductive function. This review of the literature summarises the various approaches investigated in order to obtain protection of spermatogenesis prior to radiotherapy and/or chemotherapy. Most of these pathways involve hormone therapy based on regulation of the hypothalamo-hypophyso-testicular axis. Animal models are generally used in these experiments. The various applications in man are described and discussed.
Velez de la Calle
J F
JF
GERM (Groupe d'Etude de la Reproduction chez le Mâle), Université de Rennes I. INSERM CJF 91-04.
Bauché
F
F
Jégou
B
B
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects; D005298:Fertility / Q000187:drug effects* / Q000528:radiation effects*; D006801:Humans; D007248:Infertility, Male / Q000517:prevention & control*; D008297:Male; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000532:radiotherapy*; D011878:Radiotherapy / Q000009:adverse effects
D000970:Antineoplastic Agents
Protection de la fertilité mâle lors des traitements anticancéreux: l'expérience animale.